StockData
aTYR PHARMA INC logo

aTYR PHARMA INC (ATYR) stock

ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$4.08−0.91 (-18.24%)

Close on Nov 18, 2026Market cap $400.20MP/E –Yield –

aTYR PHARMA operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

aTYR PHARMA's operating income for the twelve months ending Jun 30, 2026 was -$63.86M. For fiscal 2025 it was -$77.63M. The highest annual figure on record is -$15.91M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$77.63M–
FY2024Dec 31, 2024-$67.91M–
FY2023Dec 31, 2023-$54.92M–
FY2022Dec 31, 2022-$46.40M–
FY2021Dec 31, 2021-$34.02M–
FY2020Dec 31, 2020-$15.91M–
FY2019Dec 31, 2019-$22.98M–
FY2018Dec 31, 2018-$32.82M–
FY2017Dec 31, 2017-$47.15M–
FY2016Dec 31, 2016-$57.94M–
FY2015Dec 31, 2015-$47.62M–
FY2014Dec 31, 2014-$23.55M–
FY2013Dec 31, 2013-$19.54M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$10.88M–
Q1 FY2026Mar 31, 2026-$11.44M–
Q4 FY2025Dec 31, 2025-$14.80M–
Q3 FY2025Sep 30, 2025-$26.75M–
Q2 FY2025Jun 30, 2025-$20.31M–
Q1 FY2025Mar 31, 2025-$15.77M–
Q4 FY2024Dec 31, 2024-$15.82M–
Q3 FY2024Sep 30, 2024-$18.14M–
Q2 FY2024Jun 30, 2024-$17.32M–
Q1 FY2024Mar 31, 2024-$16.64M–
Q4 FY2023Dec 31, 2023-$15.96M–
Q3 FY2023Sep 30, 2023-$12.62M–
Q2 FY2023Jun 30, 2023-$13.56M–
Q1 FY2023Mar 31, 2023-$12.79M–
Q4 FY2022Dec 31, 2022-$7.95M–
Q3 FY2022Sep 30, 2022-$13.49M–
Q2 FY2022Jun 30, 2022-$12.58M–
Q1 FY2022Mar 31, 2022-$12.38M–
Q4 FY2021Dec 31, 2021-$8.64M–
Q3 FY2021Sep 30, 2021-$7.73M–
Q2 FY2021Jun 30, 2021-$10.45M–
Q1 FY2021Mar 31, 2021-$7.20M-487.4%
Q4 FY2020Dec 31, 2020-$4.94M–
Q3 FY2020Sep 30, 2020-$6.51M–
Q2 FY2020Jun 30, 2020-$6.32M–
Q1 FY2020Mar 31, 2020$1.86M–
Q4 FY2019Dec 31, 2019-$5.96M–
Q3 FY2019Sep 30, 2019-$5.50M–
Q2 FY2019Jun 30, 2019-$5.64M–
Q1 FY2019Mar 31, 2019-$5.88M–
Q4 FY2018Dec 31, 2018-$5.96M–
Q3 FY2018Sep 30, 2018-$6.68M–
Q2 FY2018Jun 30, 2018-$9.96M–
Q1 FY2018Mar 31, 2018-$10.22M–
Q4 FY2017Dec 31, 2017-$11.20M–
Q3 FY2017Sep 30, 2017-$10.83M–
Q2 FY2017Jun 30, 2017-$11.91M–
Q1 FY2017Mar 31, 2017-$13.21M–
Q4 FY2016Dec 31, 2016-$12.53M–
Q3 FY2016Sep 30, 2016-$13.87M–

More aTYR PHARMA figures

See a number that looks wrong?